Cargando…
Tyrosine kinase inhibitors reprogramming immunity in renal cell carcinoma: rethinking cancer immunotherapy
The immune system regulates angiogenesis in cancer by way of both pro- and antiangiogenic activities. A bidirectional link between angiogenesis and the immune system has been clearly demonstrated. Most antiangiogenic molecules do not inhibit only VEGF signaling pathways but also other pathways which...
Autores principales: | Aparicio, L. M. A., Fernandez, I. P., Cassinello, J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5599454/ https://www.ncbi.nlm.nih.gov/pubmed/28409322 http://dx.doi.org/10.1007/s12094-017-1657-7 |
Ejemplares similares
-
Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma
por: Rassy, Elie, et al.
Publicado: (2020) -
Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma
por: Bi, Kevin, et al.
Publicado: (2021) -
Complete remission with tyrosine kinase inhibitors in renal cell carcinoma
por: Wada, Yoshihiro, et al.
Publicado: (2012) -
Biomarkers for tyrosine kinase inhibitors in renal cell cancer
por: Coupe, Nicholas, et al.
Publicado: (2012) -
Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism?
por: Roviello, Giandomenico, et al.
Publicado: (2021)